Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Castle Bio Prices IPO at $16 per Share

Castle Bio Prices IPO at $16 per Share

Jul 25, 2019
|
staff reporter

NEW YORK — Skin cancer test developer Castle Biosciences said today that it has priced its planned initial public offering at $16 a share, the top end of the previously disclosed range.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Extension Call

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

All Along the Axon

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

For the Accelerator

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

Science Papers Describe New Cas9 Variant, Atlas of Human Metabolism

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Molecular Diagnostics

  1. Abbott POC Coronavirus Test Snares FDA Emergency Use Authorization

  2. FDA Fleshes Out Emergency Guidance for Coronavirus Test Developers

  3. Luminex Receives FDA Emergency Use Authorization for Coronavirus Multiplex Panel

  4. BGI Americas Gets US Emergency Use Authorization for Coronavirus Test

  5. BioMérieux Rapid Coronavirus Test Gets FDA Emergency Use Authorization

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.